MHRA-NICE real-world evidence dialogue becomes an established service as new cycle opens

What happened

On 5 November 2026 the MHRA added application details and an expression-of-interest form for the newest cycle of its MHRA-NICE real-world evidence (RWE) scientific dialogue. The regulator describes the service as now running as an established offer following a pilot phase.

The records give no further detail. We do not yet know the application deadline, how many places are available, the eligibility criteria, any fees, or how the outputs are shared with sponsors. Teams should read the MHRA's published application material before planning around the service.

Why it matters for market access

The move from pilot to established offer is the main signal. A pilot invites caution about whether the service will continue. A standing service lets evidence planners build it into UK development and launch timelines rather than treating it as a one-off opportunity.

The pairing of the regulator and NICE in a single named service also matters. Real-world evidence is often needed for both regulatory and reimbursement questions, and sponsors risk generating data that satisfies one audience but not the other. A joint dialogue is designed to reduce that risk. The records do not say how the dialogue is run, so teams should confirm what each body contributes before assuming a given level of alignment.

Scientific dialogue of this kind is generally an early engagement tool, not a decision. Participation does not, by itself, guarantee acceptance of a dataset in a later regulatory or HTA submission. The records say nothing to the contrary, and sponsors should treat it that way.

The wider payer picture on 5 November

Other records from the same day show how much pricing and reimbursement bodies are shaping evidence expectations, and how different the routes are.

In the US, CMS finalised a permanent framework for the Medicare Drug Price Negotiation Program, setting lasting policies for prices taking effect from 2029 and giving manufacturers more predictability. A separate final rule, CMS-4215-F, covers both the negotiation programme and the Medicare Prescription Drug Benefit Program. The records do not set out the rule's detailed provisions, so teams need to read the final text. CMS also issued proposed rule CMS-3484-P, 'Cutting Administrative Requirements for Excellence in Patient Care (CARE)', for Medicare and Medicaid, but its content is not yet clear from the available material.

In Portugal, Infarmed published the public funding assessment report for nonacog beta pegol (Refixia). The product is now authorised for hospital use in children under 12 with haemophilia B. That is a reminder that national funding assessments are separate, published steps after regulatory authorisation.

Sera Prognostics reported that Florida is the second state Medicaid programme to cover its PreTRM preterm birth risk test. The company is also starting a CE Mark submission for a kit-based version. This is a company report, and the records do not describe the coverage conditions.

Who is affected

The most direct audience is companies with products or devices heading for the UK, particularly those who expect real-world data to carry weight in a NICE assessment. Teams that have been waiting to see whether the pilot would continue now have an answer, though not the practical details.

Global pricing and evidence teams are also affected, because the US and UK signals point in different directions. US manufacturers now have a settled negotiation framework to plan against from 2029, while UK sponsors can seek early dialogue on evidence design. Companies in both markets will want a coherent evidence plan that serves each route.

Diagnostic and device developers should note the Sera example. Coverage from payers and certification in the EU are separate hurdles that run on separate tracks, and the records do not suggest one will speed up the other.

What to watch

First, the MHRA's application details: deadlines, scope and selection process, none of which are in the records. Second, whether the MHRA or NICE publish anything on outcomes from the pilot or earlier dialogues. Nothing in the records indicates they have. Third, the practical effect of the CMS final rules on negotiation and Part D, once manufacturers and analysts work through the text. Fourth, how the CARE proposal develops, since its substance is still unclear.